09/22/2009
10/583,046K Yong Chu ~~01-08-2009~~ Partial scope

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS	8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	9	NOV 26	MARPAT enhanced with FSORT command
NEWS	10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS	11	NOV 26	CHEMSAFE now available on STN Easy
NEWS	12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	13	DEC 01	ChemPort single article sales feature unavailable
NEWS	14	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	15	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	16	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	17	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:38:08 ON 08 JAN 2009

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:38:22 ON 08 JAN 2009

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JAN 2009 HIGHEST RN 1092924-90-7
DICTIONARY FILE UPDATES: 7 JAN 2009 HIGHEST RN 1092924-90-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L10-01082009.str





chain nodes :
1 2 3 4 6 9 10 11 15 16 17
chain bonds :
1-2 2-3 3-4 3-6 4-9 9-10 10-11 10-15 11-16 16-17
exact/norm bonds :
1-2 2-3 3-4 3-6 4-9 9-10 10-11 10-15 11-16 16-17

G1:C,S

G2:O,N

Connectivity :
6:1 E exact RC ring/chain 15:1 E exact RC ring/chain
Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 6:CLASS 9:CLASS 10:CLASS 11:Atom 15:CLASS
16:CLASS 17:Atom
Generic attributes :
1:
Saturation   : Unsaturated

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR

Full scope **not complete search**



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:38:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   743519 TO ITERATE

  0.3% PROCESSED   2000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS: 14822525 TO 14918235
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L11.str





chain nodes :
1 2 3 4 6 9 10 11 15 16 17
chain bonds :
1-2 2-3 3-4 3-6 4-9 9-10 10-11 10-15 11-16 16-17
exact/norm bonds :
1-2 2-3 3-4 3-6 4-9 9-10 10-11 10-15 11-16 16-17

G1:C,S

G2:O,N

Connectivity :
6:1 E exact RC ring/chain 15:1 E exact RC ring/chain
Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 6:CLASS 9:CLASS 10:CLASS 11:Atom 15:CLASS
16:CLASS 17:Atom
Generic attributes :
1:
Saturation : Unsaturated

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 13:39:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 743519 TO ITERATE

0.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 14822525 TO 14918235
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L12.str





chain nodes :
1 2 3 4 6 9 10 11 15 16 17
chain bonds :
1-2 2-3 3-4 3-6 4-9 9-10 10-11 10-15 11-16 16-17
exact/norm bonds :

1-2 2-3 3-4 3-6 4-9 9-10 10-11 10-15 11-16 16-17

G1:C,S

G2:O,N

Connectivity :
6:1 E exact RC ring/chain 15:1 E exact RC ring/chain
Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 6:CLASS 9:CLASS 10:CLASS 11:Atom 15:CLASS
16:CLASS 17:Atom
Generic attributes :
1:
Saturation   : Unsaturated

Element Count :
Node 11: Limited
    N,N1

Node 17: Limited
    N,N1

L5   STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5   STR



G1 C,S
G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 13:42:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   743519 TO ITERATE

```
  0.3% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:     14822525 TO 14918235
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L5

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L13.str
```






```
chain nodes :
1  2  3  4  6  8  9  10  14  15  16
chain bonds :
1-2  2-3  3-4  3-6  4-8  8-9  9-10  9-14  10-15  15-16
exact/norm bonds :
1-2  2-3  3-4  3-6  4-8  8-9  9-10  9-14  10-15  15-16


G1:C,S

Connectivity :
6:1 E exact RC ring/chain  14:1 E exact RC ring/chain
Match level :
1:Atom  2:CLASS  3:CLASS  4:CLASS  6:CLASS  8:CLASS  9:CLASS  10:Atom  14:CLASS
15:CLASS  16:Atom
Generic attributes :
1:
Saturation             : Unsaturated

Element Count :
Node 10: Limited
    N,N1

Node 16: Limited
    N,N1
```

L7 STRUCTURE UPLOADED

=> d
L7 HAS NO ANSWERS
L7 STR

Too broad scope



G1 C,S

Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 13:44:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 54614 TO ITERATE

3.7% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1078333 TO 1106227
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L14.str



chain nodes :
1 2 3 4 5 7 8 9 13 14 15
chain bonds :
1-2 2-3 3-4 3-5 4-7 7-8 8-9 8-13 9-14 14-15
exact/norm bonds :
1-2 2-3 3-4 3-5 4-7 8-9 8-13 9-14 14-15

exact bonds :
7-8

Connectivity :
5:1 E exact RC ring/chain 13:1 E exact RC ring/chain
Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:CLASS 9:Atom 13:CLASS
14:CLASS
15:Atom
Generic attributes :
1:
Saturation   : Unsaturated

Element Count :
Node 9: Limited
    N,N1

Node 15: Limited
    N,N1

L9   STRUCTURE UPLOADED

=> d
L9 HAS NO ANSWERS
L9   STR

09-22-2009

Searched scope

Examined scope



Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 13:46:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   11396 TO ITERATE

 17.6% PROCESSED   2000 ITERATIONS   1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 221522 TO   234318
PROJECTED ANSWERS: 1 TO   256

L10   1 SEA SSS SAM L9

=> d scan

L10 1 ANSWERS   REGISTRY COPYRIGHT 2009 ACS on STN
IN   Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[(2-imino-3(2H)-thiazolyl)methyl]-
     1-piperidinyl]carbonyl]-2,2-dimethylpropyl]-
MF   C22 H30 Cl N5 O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l9 full
FULL SEARCH INITIATED 13:47:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   230231 TO ITERATE

100.0% PROCESSED   230231 ITERATIONS   32 ANSWERS
SEARCH TIME: 00.00.05

L11   32 SEA SSS FUL L9

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   193.08   193.30

FILE 'CAPLUS' ENTERED AT 13:47:48 ON 08 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jan 2009 VOL 150 ISS 2
FILE LAST UPDATED: 7 Jan 2009 (20090107/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l11
L12 6 L11

=> d ibib abs hitstr tot

L12 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:564638 CAPLUS Full-text
DOCUMENT NUMBER: 143:97382
TITLE: Preparation of urea derivatives as activated blood coagulation factor X (FXa) inhibitors
INVENTOR(S): Kubo, Keiji; Imaeda, Yasuhiro
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Instant application

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058823	A1	20050630	WO 2004-JP18717	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2550012	A1	20050630	CA 2004-2550012	20041215
EP 1695961	A1	20060830	EP 2004-807076	20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20070093501	A1	20070426	US 2006-583046	20060615

PRIORITY APPLN. INFO.: JP 2003-420031 A 20031217
WO 2004-JP18717 W 20041215
OTHER SOURCE(S): MARPAT 143:97382

GI



I

AB The title compds. I [Cy represents an optionally substituted arom. hydrocarbon group or optionally substituted arom. heterocyclic group; R1 represents hydrogen or an optionally substituted hydrocarbon group; V represents C(O), S(O), or S(O)2; W represents N(R2), O, or a bond (R2 represents hydrogen or an optionally substituted hydrocarbon group); X represents optionally substituted alkylene; Y represents C(O), S(O), or S(O)2; Z represents a bond, an optionally substituted chain hydrocarbon group, etc. ; ring A represents an optionally substituted nonarom. nitrogenous heterocycle; ring B represents an optionally substituted nitrogenous heterocycle; and the dotted line indicates a single bond or double bond; provided that R1 may be bonded to R2 to form an optionally substituted nonarom. nitrogenous heterocycle and that R2 may be bonded to a substituent of X to form an optionally substituted nonarom. nitrogenous heterocycle] are prepd. Thus, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1- ((3-(3-oxo-1H-imidazo[1,5-a]imidazol-2(3H)-yl)-1-pyrrolidinyl)carbonylpropyl)urea was prepd. in several steps from 1-benzyl-3-pyrrolidinamine and imidazole-2-carbaldehyde. Compds. of this invention in vitro showed IC50 values of 10 nM to 50 nM against FXa. Formulations are given.

IT 856416-55-2P 856416-64-3P 856416-65-4P
856416-66-5P 856416-67-6P 856416-76-7P
856416-77-8P 856416-78-9P 856416-79-0P
856416-80-3P 856416-81-4P 856417-03-3P
856417-04-4P 856417-09-9P 856417-10-2P
856417-11-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of urea derivs. as activated blood coagulation factor X inhibitors)

RN 856416-55-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-[(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)methyl]-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856416-64-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[2-(5,7-dimethyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)ethyl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856416-65-4 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[2-(5,7-dimethyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)ethyl]-1-piperazinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856416-66-5 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-[2-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)ethyl]-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856416-67-6 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-[2-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)ethyl]-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856416-76-7 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-[[2,3-dihydro-3-methyl-2-(methylimino)-4-thiazolyl]methyl]-1-piperazinyl]-2-oxo-1-phenylethyl]-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 856416-77-8 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[2-[4-[[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-4-thiazolyl]methyl]-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 856416-78-9 CAPLUS
CN Urea, N'-(4-chlorophenyl)-N-[2-[4-[[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-4-thiazolyl]methyl]-1-piperazinyl]-2-oxoethyl]-N-methyl-(CA INDEX NAME)

Double bond geometry as shown.



RN 856416-79-0 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[4-[[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-4-thiazolyl]methyl]-1-piperazinyl]-3-oxopropyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 856416-80-3 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-[[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-4-thiazolyl]methyl]-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 856416-81-4 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-4-thiazolyl]methyl]-1-piperazinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 856417-03-3 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-[2-[(2Z)-2-(methylimino)-3(2H)-thiazolyl]ethyl]-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 856417-04-4 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-[[(2Z)-2-(methylimino)-3(2H)-thiazolyl]methyl]-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 856417-09-9 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[(2-imino-3(2H)-thiazolyl)methyl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856417-10-2 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[2-(2-imino-3(2H)-thiazolyl)ethyl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856417-11-3 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[(2,3-dihydro-2-imino-3-methyl-4-thiazolyl)methyl]-1-piperazinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 856418-76-3P 856418-79-6P 856418-83-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of urea derivs. as activated blood coagulation factor X inhibitors)

RN 856418-76-3 CAPLUS
CN Carbamic acid, [3-[[1-[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-4-piperidinyl]methyl]-2(3H)-thiazolylidene]-, 2-propenyl ester, [N(Z)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 856418-79-6 CAPLUS
CN Carbamic acid, [3-[2-[1-[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-4-piperidinyl]ethyl]-2(3H)-thiazolylidene]-, 2-propenyl ester, [N(Z)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 856418-83-2 CAPLUS
CN Carbamic acid, [4-[[4-[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-1-piperazinyl]methyl]-3-methyl-2(3H)-thiazolylidene]-

, 2-propenyl ester, [N(Z)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:540568 CAPLUS Full-text
DOCUMENT NUMBER: 143:78086
TITLE: Preparation of urea/carbamate derivatives as inhibitors of coagulation factor Xa for treatment of thromoboembolic disorders
INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056528	A1	20050623	WO 2004-EP13202	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10358539	A1	20050707	DE 2003-10358539	20031215
AU 2004296956	A1	20050623	AU 2004-296956	20041119
CA 2549548	A1	20050623	CA 2004-2549548	20041119
EP 1694643	A1	20060830	EP 2004-820053	20041119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1890216	A	20070103	CN 2004-80036500	20041119
BR 2004017153	A	20070306	BR 2004-17153	20041119
JP 2007513987	T	20070531	JP 2006-544246	20041119
IN 2006KN01578	A	20070504	IN 2006-KN1578	20060608

MX 2006PA06593	A	20060731	MX 2006-PA6593		20060609
KR 2006123305	A	20061201	KR 2006-711538		20060612
US 20070123509	A1	20070531	US 2006-582850		20060614
PRIORITY APPLN. INFO.:			DE 2003-10358539	A	~~20031215~~
			WO 2004-EP13202	W	20041119

OTHER SOURCE(S): CASREACT 143:78086; MARPAT 143:78086

GI



I

AB Title compds. I [D = halo, alkoxy, etc.; X = amino, O; Y = O, S, amino, etc.; R1 = H, aryl, heteroaryl, etc.; E = CH, N; Z, Z' = acyl, etc.; Q = O, amino, acyl, etc.; R4-4' = A, OH, alkoxy; T = (hetero)cyclyl, etc.] are prepd. For instance, (R)-N-(4-chlorophenyl)-N'-[2-[4-(4- fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl]urea (II) is prepd. in 3 steps from 1-methyl-4,4'-bipiperidinyl, (R)-N-(tert-butoxycarbonyl)phenylglycine and 4-chlorophenylisocyanate. II has IC50 = 6 x 10-9 M for Factor Xa. I are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or the treatment of thromboembolic diseases and for treating tumors.

IT 855524-66-2P 855524-86-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromoboembolic disorders)

RN 855524-66-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-1-phenyl-2-[4-(3-pyridinylmethyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-65-1
CMF C25 H26 Cl N5 O2

Absolute stereochemistry.



T can be piperazine [0103] Claim 19

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-86-6 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[(1R,2R)-2-methoxy-1-[[4-(3-pyridinylmethyl)-1-piperazinyl]carbonyl]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-85-5
CMF C22 H28 Cl N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:431398 CAPLUS Full-text
DOCUMENT NUMBER: 142:463595
TITLE: Preparation of N-aminoalkyl amides as agonists of the .kappa. opioid receptor useful against gastrointestinal disorders, pain, and pruritus
INVENTOR(S): Dolle, Roland E.; Chu, Guo-Hua; Gu, Minghua

PATENT ASSIGNEE(S): Adolor Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

previously cited ref

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050107355	A1	20050519	US 2003-713746	20031114
US 7160902	B2	20070109		
WO 2005049564	A1	20050602	WO 2004-US37955	20041112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-713746 A 20031114
OTHER SOURCE(S): CASREACT 142:463595; MARPAT 142:463595
GI



I



II



III

AB Amide derivs. (shown as I and II; variables defined below; e.g. N-[2-((S)-3-hydroxypyrrolidin-1-yl)-(S)-1-phenylethyl]-N-methyl-2- phenylaminoacetamide (shown as III)) are disclosed. Pharmaceutical compns. contg. these compds., and methods for their use, inter alia, for treating and/or preventing gastrointestinal disorders, pain, and pruritus (no data) are also disclosed. Although the methods of prepn. are not claimed, 36 example prepns. are included. For example, III was prepd. (45 %) by coupling of N-phenylglycine with N-[2-((S)-3-hydroxypyrrolidin-1-yl)-(S)-1-phenylethyl]-N-methylamine dihydrochloride. For I and II: R1 is H or OH; Ra is alkyl; R2 is alkyl, aryl, or aralkyl; R3 is alkyl, or R2 and R3 taken together with the atoms through

which they are connected form a 4- to 8-membered heterocyclic ring; R4 is H, alkyl, cycloalkyl, alkylcycloalkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl; Z is -(CH2)oNR5R6 or -(CH2)oC(:O)NR7R8; R5 is H, alkyl, or aryl; R6 is aryl, alkaryl, -CO(NH)pR9, or -SO2R9, provided that at least one of R5 and R6 is other than aryl; R7 is H or alkyl; R8 is alkyl, aryl, aralkyl, alkaryl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl; R9 is alkyl, cycloalkyl, alkylcycloalkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl; m is the integer 1, 2, or 3; n is the integer 1, 2, or 3; o is the integer 0, 1, 2, or 3; p is the integer 0 or 1; and the quantity (m+n) is an integer 2-5. Compds. in all the examples showed .kappa. receptor affinity (K1) <10 .mu.M. For example, III had a Ki = 0.17 nM against the human .kappa. receptor with >100.times. selectivity vs. the human .mu. and .delta. receptors and was an agonist with an EC50 = 0.05 nM. It exhibited a % A = 96.2% at a dose of 300 .mu.g, i.paw in the in vivo formalin-induced nociception assay. This compd. also blocked the action of HOAc-induced writhing when administered s.c. with an ED50 = 0.017 mg/kg.

IT 851680-59-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of N-aminoalkyl amides as agonists of .kappa. opioid receptor useful against gastrointestinal disorders, pain, and pruritus)

RN 851680-59-6 CAPLUS
CN Urea, N-[2-[(2S)-2-[[(3S)-3-hydroxy-1-pyrrolidinyl]methyl]-1-piperidinyl]-2-oxoethyl]-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:911245 CAPLUS Full-text
DOCUMENT NUMBER: 134:71594
TITLE: Preparation of indolylimidazolones as protein kinase C inhibitors
INVENTOR(S): Karabelas, Kostas; Lepisto, Matti; Sjo, Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078750	A1	20001228	WO 2000-SE1336	20000622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1192150	A1	20020403	EP 2000-946631	20000622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003502420	T	20030121	JP 2001-504916	20000622
US 6492409	B1	20021210	US 2001-743618	20010112
US 20030134886	A1	20030717	US 2002-288329	20021106
PRIORITY APPLN. INFO.:			SE 1999-2387	A 19990622
			WO 2000-SE1336	W 20000622
			US 2001-743618	A3 20010112

OTHER SOURCE(S): MARPAT 134:71594

GI



I

AB Title compds. [I; R = H, OH, NH2, (hydroxy)alkyl, aminoalkyl; R1 = H, (fluoro)alkyl, Ph, alkoxycarbonyl, etc.; 1 of R2,R3 = (un)substituted indolyl and the other =(hetero)aryl; X = O or S] were prepd. as protein kinase C inhibitors (no data). Thus, 3-azidocarbonyl-1-ethoxycarbonylindole was condensed with 2-(3-indolyl)-2-oxoethylammonium bromide and the N-methylated product heated in HOAc to give, after deprotection I (R = R1 = H, R2 = 1-methyl-3-indolyl, R3 = 3-indolyl).

IT 228252-56-0P 228252-61-7P 228252-66-2P
228253-12-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of indolylimidazolones as protein kinase C inhibitors)

RN 228252-56-0 CAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[[[[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 228252-61-7 CAPLUS
CN Urea, N-[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 228252-66-2 CAPLUS
CN Urea, N-benzo[b]thien-3-yl-N'-[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]- (CA INDEX NAME)



RN 228253-12-1 CAPLUS
CN 1H-Indole-1-carboxylic acid, 3-[[[[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:53618 CAPLUS Full-text
DOCUMENT NUMBER: 132:107951
TITLE: Preparation of imidazol-2-ones as new pharmaceutically active compounds
INVENTOR(S): Karabelas, Kostas; Lepisto, Matti; Sjo, Peter
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000002877	A2	20000120	WO 1999-SE1145		19990623
WO 2000002877	A3	20000413			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9949448	A	20000201	AU 1999-49448		19990623
EP 1095039	A2	20010502	EP 1999-933385		19990623
EP 1095039	B1	20030827			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2002531382	T	20020924	JP 2000-559107		19990623
AT 248163	T	20030915	AT 1999-933385		19990623
US 6346625	B1	20020212	US 1999-403720		19991025
PRIORITY APPLN. INFO.:			SE 1998-2538	A	19980713
			WO 1999-SE1145	W	19990623

OTHER SOURCE(S): MARPAT 132:107951

GI



I

AB The title compds. [I; Ar1 or Ar2 is (un)substituted indole, and the other group is (un)substituted arom. or heteroarom. group, preferably (un)substituted indole; X = O, S; R2 = H, OH, NH2, etc.] and their salts, useful as kinase inhibitors, esp. PKC inhibitors (no data), were prepd. E.g., a multi-step synthesis of I [Ar1 = 3-indolyl; Ar2 = 1-(3-aminopropyl)-3-indolyl; R2 = H; X = O] was given.

IT 255371-76-7P 255371-87-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of imidazol-2-ones as new pharmaceutically active compds.)

RN 255371-76-7 CAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[[[[1-(aminocarbonyl)-2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 255371-87-0 CAPLUS
CN 1H-Indole-3-propanamide, 1-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-.beta.-oxo-.alpha.-[[[(1-propyl-1H-indol-3-yl)amino]carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:421684 CAPLUS Full-text
DOCUMENT NUMBER: 131:58823
TITLE: Protein kinase C inhibiting indolylimidazolones
INVENTOR(S): Karabelas, Kostas; Lepisto, Matti; Sjo, Peter
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9932483		A1	19990701	WO 1998-SE2300	19981214
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9811285		A	19990623	ZA 1998-11285	19981209
AU 9920801		A	19990712	AU 1999-20801	19981214
EP 1042317		A1	20001011	EP 1998-965324	19981214
EP 1042317		B1	20030514		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526287		T	20011218	JP 2000-525420	19981214
AT 240317		T	20030515	AT 1998-965324	19981214
US 6337342		B1	20020108	US 1999-230710	19990129
PRIORITY APPLN. INFO.:				SE 1997-4874 A	19971223
				SE 1998-2539 A	19980713
				WO 1998-SE2300 W	19981214

OTHER SOURCE(S): MARPAT 131:58823
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The indolylimidazolones I [Ar = arom. or heteroarom. group; R1 = H, alkyl, fluoro-substituted alkyl, Ph, benzyl, alkoxycarbonyl, carbamoyl, methyl(alkylcarbamoyl); R2 = H, alkyl, aminoalkyl, hydroxyalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, (aminoalkylphenyl)alkyl, amidinothioalkyl; R3 = H, alkoxy; R4 = H or R2R4 = annulated ring substituted by hydroxyalkyl, amidinothioalkyl, aminoalkyl] and their pharmaceutically acceptable salts were prepd. as protein kinase C inhibitors with use in the treatment of inflammatory, immunol., bronchopulmonary, cardiovascular, oncol., or CNS-degenerative disorders (no data). Thus, condensation of 3-(azidocarbonyl)-1- (ethoxycarbonyl)indole with 3-(aminoacetyl)indole gave the ureidoindole II which underwent successive methylation, cyclocondensation in HOAc at 110.degree., and deblocking to give the indolylimidazolone III.

IT 228252-56-0P 228252-61-7P 228252-66-2P
228253-12-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of protein kinase C inhibiting diindolylimidazolones)

RN 228252-56-0 CAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[[[[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 228252-61-7 CAPLUS
CN Urea, N-[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 228252-66-2 CAPLUS
CN Urea, N-benzo[b]thien-3-yl-N'-[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxoethyl]- (CA INDEX NAME)



RN 228253-12-1 CAPLUS
CN 1H-Indole-1-carboxylic acid, 3-[[[[2-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1H-indol-3-yl]-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.84	228.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.92	-4.92

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:49:08 ON 08 JAN 2009